Virus-Like Particles as vaccine antigens and adjuvants: Application to chronic disease, cancer immunotherapy and infectious disease preventive strategies

Procedia in Vaccinology

Volumn 2, Issue 2, 2010, Pages 128-133

  Guillen G ^a   Aguilar, J C ^a   Duenas S ^a   Hermida, L ^a   Guzman M G ^b   Penton, E ^a   Iglesias, E ^a   Junco, J ^a   Torrens, I ^a   Lobaina, Y ^a   Muzio, V ^a   Herrera, L ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Adjuvant; Antigen; Cellular immunity; Humoral immunity; Vaccine; Virus like particles

Indexed keywords

ANTIGEN; CIGB 230; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; NUCLEOCAPSID PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIGEN;

ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; MUCOSAL IMMUNITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TH1 CELL; UTERINE CERVIX CANCER; VIRUS LIKE AGENT;

EID: 77955113941     PISSN: 1877282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.provac.2010.07.004     Document Type: Conference Paper

References (34)

1. Antonis A.F., Bruschke C.J., Rueda P., Maranga L., Casal J.I., Vela C., et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 2006, 24:5481-5490.
2. Young S.L., Wilson M., Wilson S., Beagley K.W., Ward V., Baird M.A. Transcutaneous vaccination with virus-like particles. Vaccine 2006, 24:5406-5412.
3. Dell K., Koesters R., Linnebacher M., Klein C., Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 2006, 24:2238-2247.
4. Kundig T.M., Senti G., Schnetzler G., Wolf C., Prinz Vavricka B.M., Fulurija A., et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006, 117:1470-1476.
5. Riedl P., Buschle M., Reimann J., Schirmbeck R. Binding immune-stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants. Eur J Immunol. 2002, 32:1709-1716.
6. Lobaina Y., Palenzuela D., Pichardo D., Muzio V., Guillen G., Aguilar J.C. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol. 2005, 42:289-294.
7. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol. 2002, 168:4951-4959.
8. Lobaina Y., Palenzuela D., Pichardo D., Muzio V., Guillen G., Aguilar J.C. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol. 2005, 42:289-294.
9. Pol S., Michel M.L. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines. 2006, 5:707-716.
10. Hui C.K., Lau G.K.K. Advances in immunomodulating therapy of HBV infection. Int J Med Sci. 2005, 2:24-29.
11. Aguilar A., González C.A., Cinza Z., Cabrera J., Veliz G., Moreno S.R., Alemán R., Alonso M., Figueroa N., Díaz P.A., Olivera L., Correa A., Lobaina Y., Muzio V., Guillén G., Aguilar J.C. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007, 11:394-401.
12. Iglesias E., Ruiz M., Carrazana Y., Cruz L.J., Aguilar A., Jimenez V., Carpio E., Martinez M., Perez M., Martinez C., Cruz O., Martin A., Duarte C. Chimeric proteins containing HIV-1 T cell epitopes: Expression in E. coli, purification and induction of antibodies in mice. J Biochem Mol Biol Biophys. 2001, 5:109-112.
13. Iglesias E., Thompson R., Carrazana Y., Lobaina Y., Garcia D., Sanchez J., Garcia J., Cruz O., Brown E., Martin A., Muzio V.L., Aguilar J.C. Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1. Immunol Cell Biol. 2006, 84:174-183.
14. Iglesias E., García D., Carrazana Y., Aguilar J.C., Sánchez A., Gorobaya L., Blanco A. Anti-HIV-1 and Anti-HBV Immune Responses in Mice After Parenteral and Nasal Co-Administration of a Multiantigenic Formulation. Curr HIV Res. 2008, 6:452-460.
15. Iglesias E, personal communication.
16. Cruz L.J., Iglesias E., Aguilar J.C., González L.J., Reyes O., Albericio F., Andreu D. A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjug Chem. 2004, 15(1):112-120.
17. Iglesias E., Aguilar J.C., Cruz L.J., Reyes O. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg. Mol Immunol. 2005, 42(1):99-104.
18. Cruz L.J., Cabrales A., Iglesias E., Aguilar J.C., González L.J., Reyes O. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins. Int Immunopharmacol. 2009, 9(12):1452-1459.
19. Mesa C., de León J., Rigley K., Fernández L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004, 22:3045-3052.
20. Mesa C., de León J., Fernández L.E. Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 2006, 24:2692-2699.
21. Torrens I., Mendoza O., Batte A., Reyes O., Fernandez L.E., Mesa C., Guillén G. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 2005, 23:5768-5774.
22. Junco J.A., Basulto R., Fuentes F., Bover E., Reyes O., Pimentel E., Calzada L., Castro M.D., Arteaga N., López Y., Hernández H., Bringas R., Garay H., Peschke P., Bertot J., Guillén G. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms. Adv Exp Med Biol. 2008, 617:581-587.
23. Torrens, I. Personal communication.
24. López C., Gil L., Lazo L., Menéndez I., Marcos E., Sánchez J., Valdés I., Falcón V., de la Rosa M.C., Márquez G., Guillén G., Hermida L. In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Archives of Virology 2009, 154(4):695-698.
25. Gil L, López C, Lazo L, Valdés I, Alonso R, Gambe EM, Martín J, Romero Y, Guzmán MG, Guillén G, Hermida L. 2009. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. International Immunology. doi:10.1093/intimm/dxp082.
26. Valdés I., Bernardo L., Gil L., Pavón A., Lazo L., López C., Romero Y., Menendez I., Falcon V., Betancourt L., Martín J., Chinea G., Silva R., Guzmán M.G., Guillén G., Hermida L. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009, 394:249-258.
27. Acosta-Rivero N., Rodriguez A., Mussachio A., Poutu J., Falcon V., Torres D., Aguilar J.C., Linares M., Alonso M., Perez A., Menendez I., Morales-Grillo J., Marquez G., Dueñas-Carrera S. A C-terminal truncated hepatitis C virus core protein variant assembles in vitro into virus-like particles in the absence of structured nucleic acids. Biochem Biophys Res Commun. 2005, 334(3):901-906.
28. Dueñas-Carrera S., Alvarez-Lajonchere L., Alvarez-Obregon J.C., Perez A., Acosta-Rivero N., Vazquez D.M., Martínez G., Viña A., Pichardo D., Morales J. Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem. 2002, 35:205-212.
29. Alvarez-Obregón J.C., Dueñas-Carrera S., Valenzuela C., Morales J. A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice. Vaccine 2001, 19:3940-3946.
30. Alvarez-Lajonchere L., Gonzalez M., Alvarez-Obregon J.C., Guerra I., Viña A., Acosta-Rivero N., Musacchio A., Morales J., Dueñas-Carrera S. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. Biotechnol Appl Biochem. 2006, 44:9-17.
31. Bacardí D., Amador-Cañizares Y., Cosme K., Urquiza D., Suárez J., Marante J., Viña A., Vázquez A., Concepción J., Pupo M., Aldana L., Soria Y., Romero J., Madrigal R., Martínez L., Hernández L., González I., Dueñas-Carrera S. Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus. Hum Exp Toxicol. 2009, 2(8):479-491.
32. Castellanos M., Cinza Z., Dorta Z., Veliz G., Vega H., Lorenzo I., Ojeda S., Dueñas-Carrera S., Alvarez-Lajonchere L., Martínez G., Ferrer E., Limonta M., Linares M., Ruiz O., Acevedo B., Torres D., Marquez G., Herrera L., Arus E. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J Gene Med. 2010, 12:107-116.
33. Alvarez-Lajonchere L., Shoukry N.H., Gra B., Amador-Canizares Y., Helle F., Bedard N., Guerra I., Drouin C., Dubuisson J., Gonzalez-Horta E.E., Martinez G., Marante J., Cinza Z., Castellanos M., Dueñas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat. 2009, 16:156-167.
34. Acosta-Rivero N., Aguilera Y., Falcon V., Poutou J., Musacchio A., Alvarez-Lajonchere L., Guerra I., Alvarez-Obregón J.C., Amador-Cañizares Y., Martinez G., Marante J., Aguilar J.C., Soria Y., Alvarez F., Perez A., De la Rosa M.C., Morales J., Kouri J.B., Dueñas-Carrera S. Ultrastructural and Immunological Characterization of Hepatitis C Core Protein-DNA Plasmid Complexes. Am J Immunol. 2006, 2(3):67-72.